Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy (""RITE-CI"") for Pediatric Opsoclonus-Myoclonus Syndrome : Immunomarkers and Clinical Observations

Pranzatelli, Michael R.; Tate, Elizabeth D.; Alber, Michael; Awadalla, Maha; Blumkin, Lubov; Lina, Elena S.; Leiz, Steffen; Moser, Judit

dc.contributor.author	Alber, Michael Wolfgang Hans-Peter
dc.date.accessioned	2019-11-19T08:43:57Z
dc.date.available	2019-11-19T08:43:57Z
dc.date.issued	2018
dc.identifier.issn	1439-1899
dc.identifier.uri	http://hdl.handle.net/10900/94975
dc.language.iso	en	de_DE
dc.publisher	Georg Thieme Verlag KG	de_DE
dc.relation.uri	http://dx.doi.org/10.1055/s-0037-1609038	de_DE
dc.subject.ddc	610	de_DE
dc.title	Rituximab, IVIg, and Tetracosactide (ACTH1-24) Combination Immunotherapy (""RITE-CI"") for Pediatric Opsoclonus-Myoclonus Syndrome : Immunomarkers and Clinical Observations	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190321153956_03201
utue.publikation.seiten	123-134	de_DE
utue.personen.roh	Pranzatelli, Michael R.
utue.personen.roh	Tate, Elizabeth D.
utue.personen.roh	Alber, Michael
utue.personen.roh	Awadalla, Maha
utue.personen.roh	Blumkin, Lubov
utue.personen.roh	Lina, Elena S.
utue.personen.roh	Leiz, Steffen
utue.personen.roh	Moser, Judit
dcterms.isPartOf.ZSTitelID	Neuropediatrics	de_DE
dcterms.isPartOf.ZS-Issue	2	de_DE
dcterms.isPartOf.ZS-Volume	49	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE